Apyx Medical Proposes New Share Incentive Plan with 9.5% Potential Dilution
APYX has more than doubled off its 52-week low of $1.59.
Summary
Apyx Medical filed its definitive proxy statement, proposing a new 2026 Share Incentive Plan that could dilute existing shareholders by 9.5% and detailing a significant RSU grant for its Executive Chairman.
Key Events · Corporate Governance and Compliance · APYX
-
Proposed 2026 Share Incentive Plan
The company is seeking shareholder approval for a new 2026 Share Incentive Plan authorizing 4,000,000 shares for equity awards. This represents a potential dilution of approximately 9.54% of current outstanding shares.
-
Executive Chairman RSU Grant
Stavros Vizirgianakis, the newly appointed Executive Chairman, received a grant of 450,000 Restricted Stock Units (RSUs) on June 11, 2026, with 150,000 vesting immediately. This grant is valued at approximately $2.025 million based on the current stock price.
-
Annual Shareholder Meeting Scheduled
The Annual Meeting of Stockholders is scheduled for August 6, 2026, where shareholders will vote on the election of directors, ratification of auditors, executive compensation (say-on-pay), and the proposed 2026 Share Incentive Plan.
-
2025 Executive Performance Bonuses
Named Executive Officers received discretionary bonuses at 100% of their target for 2025, driven by top-line revenue growth, reduced operating losses, and the successful commercial launch of the AYON Body Contouring System.
Analysis · APYX · Industrial Applications And Services
Apyx Medical is seeking shareholder approval for a new 2026 Share Incentive Plan that would authorize an additional 4,000,000 shares for equity awards. This represents a potential dilution of approximately 9.5% based on current outstanding shares, which could significantly impact existing shareholders. Additionally, the filing details the compensation for the newly appointed Executive Chairman, Stavros Vizirgianakis, including a substantial grant of 450,000 Restricted Stock Units (RSUs) valued at over $2 million, with a portion vesting immediately. While the company reported strong 2025 performance leading to executive bonuses, the forward-looking dilution from the proposed plan is a key concern.
At the time of this filing, APYX was trading at $4.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $188.4M. The 52-week trading range was $1.59 to $5.08. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.